TrialPediatric blood & cancer2014
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Terzah M Horton et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
35 papers cite it
this papertrialcites it